Studio Investment Management LLC Has $1.78 Million Position in Becton, Dickinson and Company $BDX

Studio Investment Management LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 15.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,303 shares of the medical instruments supplier's stock after purchasing an additional 1,369 shares during the quarter. Studio Investment Management LLC's holdings in Becton, Dickinson and Company were worth $1,775,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $29,000. Cornerstone Planning Group LLC grew its position in shares of Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $31,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 1,838 shares of company stock valued at $348,392 in the last three months. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Down 1.1%

Shares of BDX opened at $188.97 on Wednesday. The stock has a market cap of $54.16 billion, a price-to-earnings ratio of 33.99, a P/E/G ratio of 1.49 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a 50-day moving average price of $190.46 and a two-hundred day moving average price of $184.29.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Argus increased their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.